MRNA · NASDAQ
Moderna (MRNA) Stock Price & Fundamentals
Moderna (MRNA) closed at $399.01 on Oct 9, 2026, down 1.78% from the previous close of $406.24.
Share price, past year
1Y +9.04%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $399.01 |
| Sep 30, 2026 | $396.15 |
| Aug 31, 2026 | $386.98 |
| Jul 31, 2026 | $366.42 |
| Jun 30, 2026 | $366.67 |
| May 29, 2026 | $389.47 |
| Apr 30, 2026 | $374.90 |
| Mar 31, 2026 | $372.50 |
| Feb 27, 2026 | $384.39 |
| Jan 30, 2026 | $408.30 |
| Dec 31, 2025 | $384.11 |
| Nov 28, 2025 | $370.12 |
| Oct 31, 2025 | $377.61 |
Key statistics
- Market cap
- $159.20B
- P/E (TTM)
- —
- EPS (TTM)
- −$7.98
- Revenue (TTM)
- $2.23B
- Net income (TTM)
- −$3.15B
- Shares outstanding
- 399M
- Dividend yield
- —
- 52-week range
- $356.21 – $415.24
Moderna's market cap is $159.20B, based on a share price of $399.01 and 399M shares outstanding as of Jun 30, 2026.
Financials
Moderna reported revenue of $1.94B for fiscal 2025, down 39.93% from fiscal 2024.
Moderna reported a net loss of $2.82B in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.94B | −39.9% | −$2.82B | −145.2% | −$7.26 | −$2.07B |
| FY2024ended Dec 31, 2024 | $3.24B | −52.8% | −$3.56B | −110.0% | −$9.28 | −$4.06B |
| FY2023ended Dec 31, 2023 | $6.85B | −64.5% | −$4.71B | −68.8% | −$12.33 | −$3.83B |
| FY2022ended Dec 31, 2022 | $19.26B | +4.3% | $8.36B | 43.4% | $20.12 | $4.58B |
| FY2021ended Dec 31, 2021 | $18.47B | +2,200.3% | $12.20B | 66.1% | $28.29 | $13.34B |
| FY2020ended Dec 31, 2020 | $803.00M | +1,238.3% | −$747.00M | −93.0% | −$1.96 | $1.96B |
| FY2019ended Dec 31, 2019 | $60.00M | −55.6% | −$514.00M | −856.7% | −$1.55 | −$491.00M |
| FY2018ended Dec 31, 2018 | $135.07M | −34.4% | −$384.73M | −284.8% | −$4.95 | −$436.63M |
| FY2017ended Dec 31, 2017 | $205.83M | +89.9% | −$255.92M | −124.3% | −$4.18 | −$389.89M |
| FY2016ended Dec 31, 2016 | $108.40M | — | −$216.21M | −199.5% | −$3.79 | $33.59M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $145.00M | −$782.00M | −$1.97 |
| Q1 FY2026ended Mar 31, 2026 | $389.00M | −$1.34B | −$3.40 |
| Q4 FY2025ended Dec 31, 2025 | $678.00M | −$826.00M | −$2.10 |
| Q3 FY2025ended Sep 30, 2025 | $1.02B | −$200.00M | −$0.51 |
| Q2 FY2025ended Jun 30, 2025 | $142.00M | −$825.00M | −$2.13 |
| Q1 FY2025ended Mar 31, 2025 | $108.00M | −$971.00M | −$2.52 |
| Q4 FY2024ended Dec 31, 2024 | $966.00M | −$1.12B | −$2.91 |
| Q3 FY2024ended Sep 30, 2024 | $1.86B | $13.00M | $0.03 |
Company profile
- Name
- Moderna, Inc.
- Ticker
- MRNA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 325 Binney Street, Cambridge, MA 02142
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001682852
Recent SEC filings
- Sep 30, 2026
- Sep 1, 2026
- Jul 31, 2026
- Jul 31, 2026
- Jul 8, 2026
- May 11, 2026
- May 1, 2026
- May 1, 2026
Frequently asked questions
What is Moderna's stock price?
Moderna (MRNA) closed at $399.01 on Oct 9, 2026, down 1.78% from the previous close of $406.24.
What is Moderna's market cap?
Moderna's market cap is $159.20B, based on a share price of $399.01 and 399M shares outstanding as of Jun 30, 2026.
How much revenue does Moderna make?
Moderna reported revenue of $1.94B for fiscal 2025, down 39.93% from fiscal 2024.
Does Moderna pay a dividend?
Moderna's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Moderna, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures